As Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) head into 2018, the management look forward to delivering on several significant clinical and corporate milestones that are vital to their investors and the patients they plan to treat. They consider 2018 as a period of corporate evolution for company.
Zynerba plan to initiate a pivotal trial for ZYN002 in FXS that is expected to read out in 2019, commence two new Phase 2 trials in refractory epilepsies, and begin a Phase 2 plan with ‘ZYN001’ in Tourette Syndrome. The company will continue to collect a considerable amount of important statistics from its ongoing open-label extension trials in adult refractory focal epilepsy and Fragile X syndrome that they expect to publish and/or present during the year.
Zynerba is currently advancing ZYN002, the first and single patent-based, pharmaceutically-produced Cannabidiol that is made as a permeation-enhanced gel targeting transdermal delivery. The firm has a meeting scheduled with the